SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing renewed attention as crypto market sentiment fluctuates between bullish technical signals and community debates over potential price consolidation. Investors are actively discussing the symbol's struggle to break key resistance levels while weighing its long-term viability against other emerging meme coins.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing heavy social media volume as traders debate whether the semiconductor sector's record-breaking win streak is nearing a parabolic peak or represents an unbreakable AI-driven super cycle. Community members are actively sharing their high-conviction positions and frustration over the instrument's significant decay, while others continue to debate the timing of a potential sector-wide pullback.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is experiencing a parabolic, historic rally driven by persistent AI-sector demand and widespread institutional interest that has triggered consecutive daily gains. While the community is actively debating the sustainability of this bubble-like momentum versus potential imminent exhaustion, sentiment remains sharply divided between bulls expecting further record-breaking upside and bears positioning for a violent mean reversion.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors aggressively accumulate in anticipation of upcoming announcements and the project's featured presence at the XRP Las Vegas conference. Community sentiment remains polarized, with long-term holders emphasizing patience and potential utility-driven growth, while others debate the impact of volatility and market speculation.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The community is actively discussing a potential breakout for PEPE as it struggles to maintain momentum above key resistance levels. Traders remain split between those bullish on future price discovery driven by market-wide meme sentiment and others skeptical of the asset's long-term volatility.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as investors pile into the stock following confirmation of a significant order from Celestial AI, which was recently acquired by Marvell, fueling excitement about the company's role in the AI infrastructure supply chain. The community is actively discussing the stock's parabolic price action and its potential for a short squeeze, with many retail holders dismissing recent bearish short reports while eagerly anticipating potential partnerships with hyperscalers.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is trending following its robust Nasdaq IPO, with investors actively debating its long-term potential as an Amazon-backed nuclear play positioned at the intersection of AI-driven power demand and industrial infrastructure. The community is focused on the stock's significant debut performance, comparisons to existing nuclear peers, and the strategic implications of high institutional interest despite the company being in a pre-operational phase.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently surging and trending as a major short squeeze candidate following the FDA's decision to lift clinical holds on its key heart disease trial, a move that fundamentally de-risks its gene-editing pipeline. The community is focused on the massive short interest and the potential for a significant rally as traders weigh this regulatory win against an upcoming Phase 3 readout for its hereditary angioedema therapy.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community doubles down on long-term conviction and utility building despite recent price volatility and sell pressure. Investors are actively discussing the project's pivot toward business management and AI-integrated tools while maintaining a 'WAGMI' mindset to hold through market consolidation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a major rotation into semiconductor stocks following strong CPU demand narratives and industry-wide gains, which has fueled a significant short squeeze. The community is actively debating whether this momentum represents a sustainable AI-driven S-curve or an overextended bubble reminiscent of past market cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average...

Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the company's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average...

Allogene Therapeutics (NASDAQ:ALLO)  Shares Down 6%   - Should You Sell?

Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6% - What's Next...

HC Wainwright Issues Optimistic Estimate for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at HC Wainwright boosted their Q2 2026 EPS estimates for Allogene Therapeutics in a report released on Thursday, April 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.15) per share for th...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat...

Allogene Therapeutics (NASDAQ:ALLO) Trading Up 13.1% Following Analyst Upgrade

Allogene Therapeutics (NASDAQ:ALLO) Trading 13.1% Higher After Analyst Upgrade...

Allogene Therapeutics (NASDAQ:ALLO) Upgraded to "Neutral" at JPMorgan Chase & Co.

JPMorgan Chase & Co. raised Allogene Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Thursday...

Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Down - Time to Sell?

Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Down - Should You Sell...

Traders Buy Large Volume of Put Options on Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 4,437 put options on the company. This is an...

Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group raised Allogene Therapeutics to a "strong-buy" rating in a research note on Monday...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Current Price	$2.31
Prev Close	$2.35
Open	$2.33
Dividend Yield	0.00%
50-Day Moving Average	$2.39
Beta	1.63
Avg. Volume	5.46M
PE Ratio	-2.66

52-Week High	$4.46
52-Week Low	$0.8621
Market Capitalization	$765.25M
EPS (Annual)	-$0.8652
Price to Book	1.81
Revenue Per Employee	$0.00

ALLO
Allogene Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALLO News

ALLOAllogene Therapeutics Inc